Gene Therapies: Revolutionizing Disease Treatment
Gene therapies represent one of the most significant advances in modern medicine. These innovative techniques allow for the modification of genes within a patient’s cells to treat or prevent diseases, directly addressing the underlying causes of genetic conditions.
The gut microbiota and its impact on human health
The gut microbiota is the collection of microorganisms that inhabit our intestines. These microorganisms play a crucial role in our health, influencing digestive processes, the immune system, and mental health. Therefore, it is critical to conduct clinical research on the microbiota to develop effective treatments.
“Advanced Therapies are the medicine of the future”: Mercedes Zurita, researcher and head of the Cell Therapy Unit at Puerta de Hierro Hospital
We interviewed Dr. Mercedes Zurita, researcher at the Puerta de Hierro Hospital and head of the Cell Therapy Unit at this site, the only one in Spain to offer NC1 therapy for patients with spinal cord injury. This novel treatment is the result of a long and successful research in which Sermes CRO has done its bit by contributing during the development of the entire clinical phase and by providing initial funding through the Sermes Foundation for Clinical Research
Gene therapy, to be conjugated in the present tense
Gene therapy in humas is the transfer of genetic material to an individual with therapeutic purposes. The development of the gene therapy in the last 30 years has been a complicated path and full of challenges, accumulating a high number of negative results. Nevertheless, the advance in research and the development of new alternatives have made that currently gene therapy occupies a central position in the pharmaceutical market.
“Sermes CRO is committed to investing in the development of specific and technological areas”
From Sermes CRO years ago, we saw how this process came to stay and we bet on it. We invest in teams of specialized people to be able to create our own solutions and manage the information in an autonomous way. Nowadays, we have the necessary tools to give all kinds of services from our CRO/E-cro of high quality, budgetary efficiency and in the shortest time.
Sermes CRO: AEMPS approves the NC1 advance therapy drug for patients with chronic traumatic medullary injury
The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.